RAF inhibitors for treating low-grade gliomas
Patent Information
- Application Number
- JP2023527333
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-15
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-05
AI Technical Summary
を有する組成物の任意の毒性または有害な効果を超える量である。
Smart Images

Figure 00000000_0000_ABST
Abstract
Claims
1. A composition for use in treating low grade glioma (LGG) in a subject in need thereof, comprising a compound which is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharma- ceutically acceptable salt thereof, The initial dose of Compound A or a pharma- ceutical acceptable salt thereof is about 350 mg / m per week. 2 ~About 450mg / m 2 is equal to compound A of wherein the subject is under 20 years of age.
2. The initial dose of Compound A or a pharma- ceutically acceptable salt thereof is about 380 mg / m per week. 2 The composition for use according to claim 1, wherein the compound A is equal to:
3. The initial dose of Compound A or a pharma- ceutical acceptable salt thereof is about 420 mg / m per week. 2 The composition for use according to claim 1, wherein the compound A is equal to:
4. A composition for use according to any one of claims 1 to 3, characterized in that the composition is administered in combination with one or more therapeutic agents for treating a skin-related condition or disorder.
5. The composition for use according to any one of claims 1 to 3, wherein the LGG is radiographically recurrent disease or radiographically progressive disease.
6. The composition for use according to any one of claims 1 to 3, wherein the LGG is recurrent LGG or refractory LGG.
7. The composition for use according to any one of claims 1 to 3, wherein the LGG has an activating BRAF alteration or BRAF mutation.
8. The composition for use according to any one of claims 1 to 3, wherein the compound A or a pharma- ceutically acceptable salt thereof is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide.
9. The composition for use according to any one of claims 1 to 3, wherein the composition is a liquid suspension.
10. The composition for use according to any one of claims 1 to 3, wherein the composition is a tablet.
11. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered as a single dose per week.
12. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered for a period of at least 24 months.
13. The composition for use according to any one of claims 1 to 3, wherein the LGG has a BRAF mutation.
14. The composition for use according to any one of claims 1 to 3, wherein the subject has undergone one or more treatments selected from surgery, radiation, and chemotherapy prior to administering the composition, or the subject has undergone a complete or partial resection prior to administering the composition.
15. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered at a maximum dose of 600 mg of compound A or a pharma- ceutically acceptable salt thereof.
16. A composition for use in a method for treating pediatric low grade glioma (pLGG) in a subject in need thereof, comprising a compound which is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharma- ceutically acceptable salt thereof, The method includes administering the composition to the subject; wherein said initial dose of Compound A or a pharma- ceutically acceptable salt thereof is equivalent to about 350 mg / m2 to about 450 mg / m2 of Compound A per week; wherein the subject is between about 6 months and about 25 years of age. composition.
